USP11-dependent selective cIAP2 deubiquitylation and stabilization determine sensitivity to Smac mimetics

Cell Death and Differentiation

Volumn 22, Issue 9, 2015, Pages 1463-1476

  Lee, E W ^a   Seong, D ^a   Seo, J ^a   Jeong, M ^a   Lee, H K ^a   Song, J ^a  

^a Yonsei University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BIRINAPANT; DEUBIQUITINASE; INHIBITOR OF APOPTOSIS PROTEIN; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UBIQUITIN SPECIFIC PROTEASE 11; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOMIMETIC MATERIAL; BIRC3 PROTEIN, HUMAN; BV6 PEPTIDE; OLIGOPEPTIDE; SMAC PEPTIDE; THIOL ESTER HYDROLASE; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR; UBIQUITIN PROTEIN LIGASE; USP11 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CELL SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN STABILITY; UBIQUITINATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; HCT 116 CELL LINE; HEK293 CELL LINE; HELA CELL LINE; HT-29 CELL LINE; METABOLISM; MOUSE; NEOPLASMS; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

INTRACISTERNAL A-PARTICLES;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BIOMIMETIC MATERIALS; CELL LINE, TUMOR; FEMALE; HCT116 CELLS; HEK293 CELLS; HELA CELLS; HT29 CELLS; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; OLIGOPEPTIDES; SIGNAL TRANSDUCTION; THIOLESTER HYDROLASES; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN-PROTEIN LIGASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938986523     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2014.234     Document Type: Article

References (64)

1. Galluzzi L, Bravo-San Pedro JM, Vitale I, Aaronson SA, Abrams JM, Adam D et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015. Cell Death Differ 2014; 22: 58-73.
2. Hartman ML, Czyz M. Anti-apoptotic proteins on guard of melanoma cell survival. Cancer Lett 2013; 331: 24-34.
3. Kvansakul M, Hinds MG. The structural biology of BH3-only proteins. Methods Enzymol 2014; 544: 49-74.
4. Silke J, Vucic D. IAP family of cell death and signaling regulators. Methods Enzymol 2014; 545: 35-65.
5. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012; 11: 109-124.
6. Gyrd-Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer. Nat Rev Cancer 2010; 10: 561-574.
7. Lee EW, Seo J, Jeong M, Lee S, Song J. The roles of FADD in extrinsic apoptosis and necroptosis. BMB Rep 2012; 45: 496-508.
8. Bertrand MJ, Milutinovic S, Dickson KM, Ho WC, Boudreault A, Durkin J et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008; 30: 689-700.
9. Feoktistova M, Geserick P, Kellert B, Dimitrova DP, Langlais C, Hupe M et al. cIAPs block Ripoptosome formation, a RIP1/caspase-8 containing intracellular cell death complex differentially regulated by cFLIP isoforms. Mol Cell 2011; 43: 449-463.
10. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C,Wallberg F et al. The Ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPs. Mol Cell 2011; 43: 432-448.
11. Geserick P, Hupe M, Moulin M,Wong WW, Feoktistova M, Kellert B et al. Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment. J Cell Biol 2009; 187: 1037-1054.
12. Schilling R, Geserick P, Leverkus M. Characterization of the ripoptosome and its components: implications for anti-inflammatory and cancer t. Methods Enzymol 2014; 545: 83-102.
13. Vandenabeele P, Bertrand MJ. The role of the IAP E3 ubiquitin ligases in regulating pattern-recognition receptor signalling. Nat Rev Immunol 2012; 12: 833-844.
14. Bai L, Smith DC, Wang S. Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol Ther 2014; 144: 82-95.
15. Vucic D, Deshayes K, Ackerly H, Pisabarro MT, Kadkhodayan S, Fairbrother WJ et al. SMAC negatively regulates the anti-apoptotic activity of melanoma inhibitor of apoptosis (ML-IAP). J Biol Chem 2002; 277: 12275-12279.
16. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/TRAILor anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med 2002; 8: 808-815.
17. Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P et al. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalphadependent apoptosis. Cell 2007; 131: 669-681.
18. Vince JE, Wong WW, Khan N, Feltham R, Chau D, Ahmed AU et al. IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis. Cell 2007; 131: 682-693.
19. Petersen SL, Wang L, Yalcin-Chin A, Li L, Peyton M, Minna J et al. Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis. Cancer Cell 2007; 12: 445-456.
20. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard C, Enwere E et al. Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation. Proc Natl Acad Sci USA 2008; 105: 11778-11783.
21. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, Zobel K, Deshayes K et al. c-IAP1 and c-IAP2 are critical mediators of tumor necrosis factor alpha (TNFalpha)-induced NF-kappaB activation. J Biol Chem 2008; 283: 24295-24299.
22. Petersen SL, Peyton M, Minna JD, Wang X. Overcoming cancer cell resistance to Smac mimetic induced apoptosis by modulating cIAP-2 expression. Proc Natl Acad Sci USA 2010; 107: 11936-11941.
23. Feltham R, Bettjeman B, Budhidarmo R, Mace PD, Shirley S, Condon SM et al. Smac mimetics activate the E3 ligase activity of cIAP1 protein by promoting RING domain dimerization. J Biol Chem 2011; 286: 17015-17028.
24. Darding M, Feltham R, Tenev T, Bianchi K, Benetatos C, Silke J et al. Molecular determinants of Smac mimetic induced degradation of cIAP1 and cIAP2. Cell Death Differ 2011; 18: 1376-1386.
25. Mei Y, Hahn AA, Hu S, Yang X. The USP19 deubiquitinase regulates the stability of c-IAP1 and c-IAP2. J Biol Chem 2011; 286: 35380-35387.
26. Goncharov T, Niessen K, de Almagro MC, Izrael-Tomasevic A, Fedorova AV, Varfolomeev E et al. OTUB1 modulates c-IAP1 stability to regulate signalling pathways. EMBO J 2013; 32: 1103-1114.
27. Steinhart L, Belz K, Fulda S. Smac mimetic and demethylating agents synergistically trigger cell death in acute myeloid leukemia cells and overcome apoptosis resistance by inducing necroptosis. Cell Death Dis 2013; 4: e802.
28. Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A et al. The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. Clin Cancer Res 2013; 19: 1784-1794.
29. Bai L, McEachern D, Yang CY, Lu J, Sun H,Wang S. LRIG1 modulates cancer cell sensitivity to Smac mimetics by regulating TNFalpha expression and receptor tyrosine kinase signaling. Cancer Res 2012; 72: 1229-1238.
30. Varfolomeev E, Moradi E, Dynek JN, Zha J, Fedorova AV, Deshayes K et al. Characterization of ML-IAP protein stability and physiological role in vivo. Biochem J 2012; 447: 427-436.
31. Muller-Sienerth N, Dietz L, Holtz P, Kapp M, Grigoleit GU, Schmuck C et al. SMAC mimetic BV6 induces cell death in monocytes and maturation of monocyte-derived dendritic cells. PLoS ONE 2011; 6: e21556.
32. Maas C, Tromp JM, van Laar J, Thijssen R, Elias JA, Malara A et al. CLL cells are resistant to smac mimetics because of an inability to form a ripoptosome complex. Cell Death Dis 2013; 4: e782.
33. Tchoghandjian A, Jennewein C, Eckhardt I, Rajalingam K, Fulda S. Identification of noncanonical NF-kappaB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells. Cell Death Dis 2013; 4: e564.
34. Burkhart RA, Peng Y, Norris ZA, Tholey RM, Talbott VA, Liang Q et al. Mitoxantrone targets human ubiquitin-specific peptidase 11 (USP11) and is a potent inhibitor of pancreatic cancer cell survival. Mol Cancer Res 2013; 11: 901-911.
35. Yamaguchi T, Kimura J, Miki Y, Yoshida K. The deubiquitinating enzyme USP11 controls an IkappaB kinase alpha (IKKalpha)-p53 signaling pathway in response to tumor necrosis factor alpha (TNFalpha). J Biol Chem 2007; 282: 33943-33948.
36. Sun W, Tan X, Shi Y, Xu G, Mao R, Gu X et al. USP11 negatively regulates TNFalphainduced NF-kappaB activation by targeting on IkappaBalpha. Cell Signal 2010; 22: 386-394.
37. Lamb JA, Ventura JJ, Hess P, Flavell RA, Davis RJ. JunD mediates survival signaling by the JNK signal transduction pathway. Mol Cell 2003; 11: 1479-1489.
38. Passante E, Wurstle ML, Hellwig CT, Leverkus M, Rehm M. Systems analysis of apoptosis protein expression allows the case-specific prediction of cell death responsiveness of melanoma cells. Cell Death Differ 2013; 20: 1521-1531.
39. Moulin M, Anderton H, Voss AK, Thomas T, Wong WW, Bankovacki A et al. IAPs limit activation of RIP kinases by TNF receptor 1 during development. EMBO J 2012; 31: 1679-1691.
40. Cheung HH, Beug ST St, Jean M, Brewster A, Kelly NL, Wang S et al. Smac mimetic compounds potentiate interleukin-1beta-mediated cell death. J Biol Chem 2010; 285: 40612-40623.
41. Cohen S, Bruchim I, Graiver D, Evron Z, Oron-Karni V, Pasmanik-Chor M et al. Platinumresistance in ovarian cancer cells is mediated by IL-6 secretion via the increased expression of its target cIAP-2. J Mol Med (Berl) 2013; 91: 357-368.
42. Lu J, McEachern D, Sun H, Bai L, Peng Y, Qiu S et al. Therapeutic potential and molecular mechanism of a novel, potent, nonpeptide, Smac mimetic SM-164 in combination with TRAIL for cancer treatment. Mol Cancer Ther 2011; 10: 902-914.
43. Ziegler DS, Wright RD, Kesari S, Lemieux ME, Tran MA, Jain M et al. Resistance of human glioblastoma multiforme cells to growth factor inhibitors is overcome by blockade of inhibitor of apoptosis proteins. J Clin Invest 2008; 118: 3109-3122.
44. Carter BZ, Mak PY, Mak DH, Shi Y, Qiu Y, Bogenberger JM et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents. J Natl Cancer Inst 2014; 106: djt440.
45. Collins R, Trowman R, Norman G, Light K, Birtle A, Fenwick E et al. A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormonerefractory prostate cancer. Br J Cancer 2006; 95: 457-462.
46. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72.
47. Schutz FA, Buzaid AC, Sartor O. Taxanes in the management of metastatic castrationresistant prostate cancer: Efficacy and management of toxicity. Crit Rev Oncol Hematol 2014; 91: 248-256.
48. Dhanasekaran DN, Reddy EP. JNK signaling in apoptosis. Oncogene 2008; 27: 6245-6251.
49. Sabapathy K. Role of the JNK pathway in human diseases. Prog Mol Biol Transl Sci 2012; 106: 145-169.
50. Kuntzen C, Sonuc N, De Toni EN, Opelz C, Mucha SR, Gerbes AL et al. Inhibition of c-Jun-N-terminal-kinase sensitizes tumor cells to CD95-induced apoptosis and induces G2/M cell cycle arrest. Cancer Res 2005; 65: 6780-6788.
51. Liu J, Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res 2005; 15: 36-42.
52. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009; 138: 389-403.
53. Camus S, Higgins M, Lane DP, Lain S. Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6. FEBS letters 2003; 536: 220-224.
54. Lee EW, Kim JH, Ahn YH, Seo J, Ko A, Jeong M et al. Ubiquitination and degradation of the FADD adaptor protein regulate death receptor-mediated apoptosis and necroptosis. Nat Commun 2012; 3: 978.
55. Kim SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK et al. Death induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in primary human esophageal epithelial cells. J Biol Chem 2004; 279: 40044-40052.
56. Lee EW, Lee MS, Camus S, Ghim J, Yang MR, Oh W et al. Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J 2009; 28: 2100-2113.
57. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D et al. ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia 2004; 6: 1-6.
58. Hong Y, Downey T, Eu KW, Koh PK, Cheah PY. A 'metastasis-prone' signature for earlystage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics. Clin Exp Metastasis 2010; 27: 83-90.
59. Talantov D, Mazumder A, Yu JX, Briggs T, Jiang Y, Backus J et al. Novel genes associated with malignant melanoma but not benign melanocytic lesions. Clin Cancer Res 2005; 11: 7234-7242.
60. Hong Y, Ho KS, Eu KW, Cheah PY. A susceptibility gene set for early onset colorectal cancer that integrates diverse signaling pathways: implication for tumorigenesis. Clin Cancer Res 2007; 13: 1107-1114.
61. Grone J, Lenze D, Jurinovic V, Hummel M, Seidel H, Leder G et al. Molecular profiles and clinical outcome of stage UICC II colon cancer patients. Int J Colorectal Dis 2011; 26: 847-858.
62. Xu L, Shen SS, Hoshida Y, Subramanian A, Ross K, Brunet JP et al. Gene expression changes in an animal melanoma model correlate with aggressiveness of human melanoma metastases. Mol Cancer Res 2008; 6: 760-769.
63. Loboda A, Nebozhyn MV, Watters JW, Buser CA, Shaw PM, Huang PS et al. EMT is the dominant program in human colon cancer. BMC Med Genomics 2011; 4: 9.
64. Jonsson G, Busch C, Knappskog S, Geisler J, Miletic H, Ringner M et al. Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clin Cancer Res 2010; 16: 3356-3367.